Lonza Expands HPAPI Capacity at Visp
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Lonza expands HPAPI capacity at Visp
Lonza is expanding highly potent active pharmaceutical ingredient and antibody-drug conjugate payload-linker manufacturing capacity at its Visp site in Switzerland. The investment will enhance the company’s drug-linker centre of excellence and add commercial-scale capabilities for complex HPAPI and ADC payload-linker molecules. The expansion will be located within an existing GMP facility and will include additional production and purification c…
Lonza announced plans to expand its payload linker competence center and increase payload linker production capacity at its Visp site. This expansion will create new commercial-scale capacity for the production of highly complex and potent pharmaceutical ingredients...
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
